Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FGEP2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,213
Award facts
- Contract value 100% obligated
- $14,212.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $14,212.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, issued on November 28, 2025, with an ultimate completion date of December 19, 2025, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's recently established Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award contract designated SPE2DR that was awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036.
The PPV-G GEN V represents a cornerstone $30.3 billion acquisition strategy establishing multiple regional prime vendor contractors to supply the Department of Defense's worldwide military healthcare facilities with comprehensive pharmaceutical products and medical consumables. DMS Pharmaceutical Group's established performance delivering oncology treatments, biologics including immunosuppressants, vaccines, and specialty pharmaceuticals positions the company as a critical supplier within the federal pharmaceutical supply chain. As the sole vendor on this delivery order with no identified subcontractors, DMS Pharmaceutical Group will directly fulfill the military medical system's pharmaceutical requirements under this contract structure spanning a 30-month base period with three optional 30-month renewal periods.
Quick answers
Who was awarded contract SPE2DR26FGEP2?
SPE2DR26FGEP2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26FGEP2 worth?
The government has obligated $14,213 on SPE2DR26FGEP2.
Is contract SPE2DR26FGEP2 an order under another contract?
Yes. SPE2DR26FGEP2 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGEP2 competed?
The extent of competition for SPE2DR26FGEP2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award